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14.3.5 OTHER RELEVANT BACTERIA
1. INTRODUCTION
jj Chronic pulmonary infection, defined as more than 50% culture positivity within the prece-
ding 12 months, is a leading cause of morbidity and mortality in CF patients. 
jj The main bacterial pathogens are Staphylococcus aureus and Pseudomonas aeruginosa, 
but other Gram-negative bacteria including Stenotrophomonas maltophilia, Achromobacter 
xylosoxidans, Inquilinus limosus, Ralstonia spp., Pandoraea apista and anaerobic bacteria 
are of emerging interest. 
js Many of these bacteria have similar phenotypic characteristics rendering their identifi-
cation challenging. 
js They are characterized by a wide spectrum of intrinsic and acquired mechanisms of 
antibiotic resistance. Table 1 shows the profile of intrinsic resistance of S. maltophilia 
and A. xylosoxidans.
js The pathogenic relevance of these bacteria, however, remains controversial to 
date.
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 Table 1:  Intrinsic antibiotic resistance of S. maltophilia  
and A. xylosoxidans1-3
S. maltophilia A. xylosoxidans
Amoxicillin/clavulanate R R
Ticarcillin/clavulanate - -
Piperacillin/tazobactam R -
Cefazolin R R
Ceftriaxone R R
Ceftazidime R -
Cefepime R R
Cefuroxime R R
Aztreonam R R
Ertapenem R R
Imipenem R -
Meropenem R -
Linezolid R R
Clindamycin R R
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S. maltophilia A. xylosoxidans
Fusidic acid R R
Rifampicin R R
Daptomycin R R
Macrolides R R
Ciprofloxacin - R
Aminoglycosides R R
TMP/SMX - -
Fosfomycin R R
Minocycline - -
Tigecycline - -
Colistin - -
2. STENOTROPHOMONAS MALTOPHILIA
jj S. maltophilia is an obligate aerobic, gram-negative rod, which can be found in aqueous 
sources.
jj Like other CF pathogens, S. maltophilia is able to form a biofilm, which impairs phagocyto-
sis and the penetration of antibiotic drugs. 
jj The prevalence of S. maltophilia in the lower respiratory tract of CF patients is reported 
between 15 to 25%.
jj In one single center cohort study none of the patients shared the same strain of S. malto-
philia, indicating that no crossinfection has occurred. 
jj Outcomes:
js Patients with chronic S. maltophilia infection were found to have an increased risk of 
pulmonary exacerbations compared with patients without detection of S. maltophilia in 
a model adjusted for age, pancreatic insufficiency, infection with P. aeruginosa, body 
mass index and baseline lung function. Moreover, chronic S. maltophilia infection was 
associated with an almost three-fold increased risk of death or lung transplant in CF 
patients.
js Conversely, no significant difference in long-term lung function was found in patients 
with chronic S. maltophilia infection compared to S. maltophilia-negative patients. It has 
also been shown that a chronic infection with S. maltophilia does not alter lung function 
recovery after a pulmonary exacerbation. Along the same line, specific antibiotic treat-
ments (e.g. TMP/SMX or levofloxacin) did not affect the course of lung function following 
a pulmonary exacerbation regardless of the length of therapy.
jj In light of these data, the question whether S. maltophilia is a true CF pathogen 
or an innocent bystander remains unclear. As such, there is no recommendation 
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concerning specific antibiotic therapy. In our opinion, chronic infection with S. maltophilia 
is a surrogate marker of disease severity in CF patients.
3. ACHROMOBACTER XYLOSOXIDANS
jj A. xylosoxidans is an aerobic, gram negative rod found in 2 to 20% of the CF population 
with an increasing prevalence. 
jj Similar to CF patients infected with P. aeruginosa and S. maltophilia, patients with chronic 
pulmonary infection with A. xylosoxidans show biofilm-like clusters in sputum. 
jj Cross-infection as a direct consequence of patient-to-patient contact has been 
reported. Thus, in contrast to CF patients with S. maltophilia infection, we recommend to 
segregate these patients more strictly.
jj Outcomes:
js A recent study has shown that patients chronically infected with A. xylosoxidans com-
pared to patients with P. aeruginosa infection had similar levels of inflammatory parame-
ters and a similar rate of lung function decline one year after development of chronic 
infection. 
jj A main problem is the high rate of intrinsic antimicrobial resistance of the A. xylo-
soxidans species. At the moment, piperacillin/tazobactam is probably the most active 
anti-achromobacterial agent. Examples of protocols for the treatment of A. xylosoxidans 
are shown in Table 2 and suggested drug doses in Table 3. The choice of treatment will 
depend on the severity of symptoms, the need of concomitant treatment for P. aeruginosa, 
the susceptibility testing results and patient drug tolerance.
jj Due to the lack of more data, the relevance of chronic infection with A. xylosoxidans 
and the role of its treatment remain unclear.
 Table 2:  Examples of protocols used for the treatment of A. xylosoxidans1,4,5*
Protocol 14 TMP/SMX orally and/or minocycline orally and/or chloramphenicol orally
Protocol 24 Piperacillin/tazobactam IV or meropenem IV or imipenem IV or temocillin IV
Protocol 35 Meropenem or imipenem + TMP/SMX or ciprofloxacin or minocycline
Protocol 41 1st line: piperacillin/tazobactam, meropenem, TMP/SMX
2nd line: ceftazidime, minocycline, colistin, chloramphenicol
Suggested combination: meropenem + ciproflocacin or levofloxacin
Alternative combinations: 
       - meropenem + minocycline 
       - levofloxacin + chloramphenicol + colistin inhaled
Chloramphenicol and temocillin are not avalaible in Switzerland
*Standard treatment duration of 14 days
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Table 3:  Doses of antibiotics used for Achromobacter xylosoxidans4-6  
(in alphabetical order)
Antibiotic Dosage Comments
IV Ceftazidime 3-4 g mg every 8h
(150-250 mg/kg/day)
Maximum 12 g/24h
Ciprofloxacin 400 mg every 12h
Colistin <40kg 1MU every 8h
40-60kg 1.5MU every 8h
>60kg 2MU every 8h
Imipenem-cilastatin 1g every 6-8h
(60-100 mg/kg/day)
Meropenem If <40kg 1.5g every 8h
If >40kg 2g every 8h
Piperacillin/
tazobactam
4.5 g every 6-8h Maximum 16 g/24h  
(of piperacillin)
Ticarcillin/clavulanic 3.1 g every 6-8h Not available in  
Switzerland
TMP/SMX 160-240 mg of TMP every 
12h or
4-5 mg/kg of TMP every 12h
Maximum 240 mg of  
TMP every 12h
Oral Chloramphenicol 500 mg every 6h
Ciprofloxacin 750 mg every 12h
Levofloxacin 500 mg every 12h
Minocycline 100 mg every 12h
TMP/SMX 160/800 mg every 8h or 
320/1600 mg every 12h
Inhaled Colistin 1 -2 MU every 12h
4. INQUILINUS LIMOSUS
jj It is a gram-negative bacterium that was first identified in 1999. It has a mucoid phenotype 
which may contribute to colonization.
jj Its clinical significance and pathogenicity are unknown but some cases of declining lung 
function and respiratory exacerbations have been reported.
jj It has a multi-resistant profile to several antimicrobial drugs. Antibiotic susceptibility testing 
and concomitant infection with P. aeruginosa orient treatment.
Note: susceptibility to ceftazidime, carbapenems and ciprofloxacin has been reported, but, 
despite treatment, in some cases I. limosus persisted in sputum cultures. 
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5. RALSTONIA SPP
jj Ralstonia spp represents a group of Gram-negative bacilli, first described as a genus in 1995.
jj Its prevalence in CF is not known: frequently misidentified as B.cepacia complex.
jj Its clinical significance and pathogenicity are unknown.
jj Antibiotic susceptibility testing and concomitant infection with P. aeruginosa will orient 
treatment.
6. PANDORAEA SPP 
jj Pandoraea spp represent a group of gram-negative bacilli described in 2000.
jj Its prevalence in CF is unknown
js It has been frequently misidentified as other species, such as B.cepacia complex or 
Ralstonia spp.
js P. apista is the species that has been associated to CF.
jj Its clinical significance and pathogenicity are unknown: some cases of declining lung func-
tion and patient-to-patient cross contamination have been reported. 
7. ANAEROBIC BACTERIA
jj CF-patients have a reduced mucociliary clearance and persistent mucus hypersecretion 
resulting in an oxygen gradient within the airways. Hypoxic regions - e.g. behind mucus 
plugs - provide optimal conditions for the growth of anaerobic bacteria that probably mi-
grate from the oropharynx. Co-infection with P. aeruginosa might enhance the hypoxic 
(anaerobic) conditions. 
jj Anaerobic bacteria are not detected by routine culture methods thus masking the true pre-
valence of anaerobic infections. Following a strict anaerobic culture technique, anaerobic 
bacteria are detected in more than 60% of sputum samples from adult CF patients. The most 
frequent organisms detected are Prevotella, Veillonella, Propionibacterium and Actinomyces.
jj Outcomes:
js Antibiotic treatment directed against aerobe species had just a minimal effect on the 
abundance of anaerobe species.
js No significant difference in lung function between anaerobe-positive vs. anaerobe- 
negative CF patients was found. Moreover, specific treatment has not yet been shown 
to have a beneficial impact on patient outcome. 
jj Taken together, infection with anaerobic bacteria appears to be common in CF-patients 
and treatment is difficult. However, the clinical relevance of these bacteria in CF 
patients is not clear. 
8. BORDETELLA SPECIES
Authors: Angela Koutsokera, Oriol Manuel, Alain Sauty, Nicolas Mü ller, Christian Benden
jj Pertussis (‘whooping cough’) is caused by the gram-negative B. pertussis. Other spe-
cies which can cause respiratory infection are B. parapertussis, B. bronchiseptica and 
B. holmesii. 
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jj The reported incidence of Bordetella positive cultures in pediatric and adult CF patients is 
approximately 5%. However, pertussis is probably underdiagnosed in CF because
js diagnosis requires a high index of suspicion and specific testing
js symptoms are non-specific and overlap with those of CF pulmonary exacerbations
js the classic catarrhal, paroxysmal and convalescent phases may not be evident in pre-
viously vaccinated patients. Moreover, it is not known in what ways the chronic use of 
antibiotics (such as azithromycin or TMP/SMX) may modify the clinical manifestations or 
the risk of developing pertussis.
jj In the general population, when symptoms last up to 4 weeks, a nasopharyngeal swab 
culture and PCR for Bordetella species are recommended for the diagnosis of pertussis. 
After 4 weeks of symptoms, serology is recommended mostly for epidemiological purpo-
ses. In CF the time-point of symptoms initiation may be difficult to establish.
js Swabs used for B. pertussis should not contain cotton (fatty acids toxic for B. pertussis). 
js Cultures have a higher sensitivity during the first 2 weeks of symptoms (60%) but this 
sensitivity decreases with time and by the recent use of antibiotics. The results may take 
7-10 days. 
js PCR is not affected by the use of antibiotics, is rapidly available but may be false 
positive.
js Serologic testing can confirm the diagnosis of pertussis in the following situations 
 – When the acute phase sampling is done early: diagnosis is confirmed by a ≥4-fold 
increase in the titers of IgA or IgG to pertussis toxin between the acute and the 
convalescent phase (i.e. 4 weeks after the acute phase sample) or 
 – When the acute phase sampling was delayed: diagnosis can be established if the 
titer of the acute phase sample is already high (IgG anti-pertussis toxin ≥100-125 EU/
ml) or if the titer decreases at a subsequent sampling after 4 weeks.
js If results are discordant among these tests, patients should be treated for pertussis.
jj Management:
js Supportive, symptomatic care. 
js Pertussis is highly contagious and the following are recommended: 
a) isolation with droplet precautions until 5 days of effective treatment or after 3 weeks 
in untreated patients, 
b) pertussis cases should be reported to the local public health authorities, 
c) post exposure chemoprophylaxis should be considered for close asymptomatic 
contacts.
js The antibiotic treatment should be started within the first 3 weeks of evolution.
 – Azithromycin orally for 5 days: 500mg 1x/day on day 1, followed by 250 mg 1x/day 
during days 2 to 5 or
 – Clarithromycin 500 mg 2x/day orally for 7 days or
 – TMP/SMX 800/160mg orally 2x/day for 14 days 
jj Vaccination (see also Chapter “Vaccination” ): 
js Childhood vaccination for pertussis should be followed by booster Tdap vaccination 
(Boostrix®) in adulthood (1 dose at the age of 25-29). This applies for CF patients and 
also for close family members of CF patients. 
js Although in the current guidelines it is not recommended for the general population, CF 
patients may benefit from the use of Tdap (instead of Td) every 10-20 years.
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